サンプル依頼リスト カート
  • English
  • Korean
表紙：急性片頭痛治療薬の世界市場-2023年～2030年
市場調査レポート
商品コード
1319132

急性片頭痛治療薬の世界市場-2023年～2030年

Global Acute Migraine Drugs Market - 2023-2030
出版日: | 発行: DataM Intelligence | ページ情報: 英文 122 Pages | 納期: 約2営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
急性片頭痛治療薬の世界市場-2023年～2030年
出版日: 2023年07月31日
発行: DataM Intelligence
ページ情報: 英文 122 Pages
納期: 約2営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

市場概要

急性片頭痛治療薬の世界市場は、2022年に25億米ドルに達し、2023～2030年の予測期間にCAGR 8.1%で成長し、2030年には45億米ドルに達すると予測されます。新薬の臨床試験の増加が、急性片頭痛治療薬の市場動向の需要を押し上げています。

世界の急性片頭痛治療薬市場は近年著しい成長を遂げています。急性片頭痛治療のための新しい治療法の開発には大きな進歩が見られます。エレヌマブ、フレマネズマブ、ガルカネズマブなどのモノクローナル抗体は予防的治療薬として承認を得ており、急性片頭痛治療への応用も検討されています。市場は競争が激しく、複数の主要企業が急性片頭痛治療薬の研究開発および商業化に積極的に関与しています。

世界の急性片頭痛治療薬市場は、片頭痛の有病率の増加、革新的な薬剤に対する需要の高まり、認知度と診断の向上、急性片頭痛治療薬の技術的進歩などの要因によって牽引されています。

市場力学

革新的薬剤への需要の高まりが急性片頭痛治療薬市場の成長を牽引

革新的な薬剤への需要は、より便利で効果的な治療方法への要望によっても牽引されています。点鼻薬、注射剤、経皮パッチなどの新しいドラッグデリバリーシステムの開発は、薬効を高め、患者のコンプライアンスを改善し、片頭痛の症状をより早く緩和することを目的としています。これらの進歩は、患者の進化するニーズや嗜好に対応することで市場の成長に寄与しています。

片頭痛は複雑な神経疾患であり、症状を緩和し患者の転帰を改善するために、より効果的で的を絞った治療が継続的に必要とされています。そして、急性片頭痛のより良い治療のための革新的な薬剤につながる臨床試験が増加しています。

例えば、2023年6月13日、不安、うつ病、その他の中枢神経系（CNS）障害を抱える人々の治療状況の変革を目指す後期臨床段階のバイオ医薬品企業であるVistagen社は、欧州特許庁（EPO）が、当社の5つの迅速発症型治験用神経活性フェリン治療薬の1つであるPH80点鼻スプレーの鼻腔内投与による片頭痛治療に関する特許を付与する意向を示したと発表しました。

意識と診断の向上も急性片頭痛治療薬市場の成長を牽引

認知度の向上により、片頭痛の症状が現れた時点で医療機関を受診する傾向が高まり、早期介入・早期治療につながっています。早期の治療は、より早く症状を緩和し、片頭痛の進行を予防できる可能性があるため、より良い結果につながります。早期介入を重視するあまり、片頭痛発作時に迅速な緩和をもたらす急性片頭痛治療薬の需要が高まっています。

片頭痛に対する認識が高まるにつれて、医療従事者は片頭痛の診断と管理についてますます知識を深めています。医学会や団体は、片頭痛の治療に関するガイドラインや推奨事項を発表し、エビデンスに基づいたアプローチを強調しています。これらのガイドラインは医師の処方パターンに影響を与え、急性片頭痛治療薬の使用量増加に寄与しています。

薬剤コストの高さが市場の成長を妨げる

薬剤の価格が高いため、人口のかなりの部分、特に十分な健康保険に加入していない人々や経済的に余裕のない人々が薬剤にアクセスできなくなる可能性があります。そのため、片頭痛へのアクセスが妨げられ、適切な治療が受けられなくなる可能性があります。患者が必要な薬剤を入手できるようにするためには、薬剤の購入しやすさが重要な要素となります。

薬剤費が高額になると、償還や保険適用の面で課題が生じることがあります。保険会社は、高額な片頭痛治療薬に対して、厳しい保険適用規定や高額な自己負担を要求する場合があり、患者のアクセスが制限されます。その結果、治療を受けるのが遅れたり、より効果の低い、あるいはより安価な代替薬を使用することになり、患者の転帰に影響を与えます。

COVID-19の影響分析

COVID-19の流行は、世界の急性片頭痛治療薬市場に大きな影響を与えました。新しい急性片頭痛治療薬の臨床試験は、パンデミックのために遅延や中断を経験した可能性があります。患者募集の制限、現地訪問の制限、COVID-19関連研究の優先順位付けなどが臨床試験の進行に影響を与えました。こうした遅延は、新たな治療法の市場導入に影響を与えた可能性があります。

ロシア・ウクライナ紛争影響分析

ロシア・ウクライナ紛争は、世界の急性片頭痛治療薬市場に中程度の影響を及ぼすと推定されます。紛争は、医薬品や急性片頭痛薬の原材料の輸送を含むサプライチェーンの混乱につながる可能性があります。国境閉鎖、貿易制限、セキュリティ対策の強化は物資の移動を妨げ、急性片頭痛治療薬の入手に遅延や不足を引き起こす可能性があります。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 影響要因
    • 促進要因
      • 革新的医薬品に対する需要の高まり
      • 意識と診断の向上
    • 抑制要因
      • 薬剤の高コスト
    • 機会
      • 技術の進歩と新薬の上市
    • 影響分析

第5章 産業分析

  • ポーターの5フォース分析
  • サプライチェーン分析
  • 価格分析
  • 規制分析

第6章 COVID-19分析

第7章 薬剤タイプ別

  • トリプタン
  • 非ステロイド性抗炎症薬（NSAIDs）
  • エルゴットアルカロイド
  • その他

第8章 投与経路別

  • 経口
  • 非経口
  • 経鼻
  • その他

第9章 流通チャネル別

  • 病院薬局
  • 小売薬局
  • オンライン薬局

第10章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • スペイン
    • イタリア
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他アジア太平洋地域
  • 中東・アフリカ

第11章 競合情勢

  • 競合シナリオ
  • 市況/シェア分析
  • M&A分析

第12章 企業プロファイル

  • Teva Pharmaceuticals
    • 会社概要
    • 製品ポートフォリオと説明
    • 財務概要
    • 主な発展
  • F Hoffmann-la Roche Ltd
  • Johnson & Johnson
  • Pfizer Inc.
  • AstraZeneca
  • Amgen Inc.
  • Merck & Co.
  • Novartis AG
  • Eli Lilly and Company
  • Sun Pharma

第13章 付録

目次
Product Code: PH4243

Market Overview

Global Acute Migraine Drugs Market reached US$ 2.5 billion in 2022 and is expected to reach US$ 4.5 billion by 2030 growing with a CAGR of 8.1% during the forecast period 2023-2030. The growing clinical trials for novel drugs are driving up demand for acute migraine drugs market trends.

The global acute migraine drugs market experiencing significant growth in recent years. There have been significant advancements in the development of new therapies for acute migraine treatment. These monoclonal antibodies, such as erenumab, fremanezumab, and galcanezumab, have gained approval as preventive treatments and are also being explored for their potential use in acute migraine treatment. The market is highly competitive, with several key players actively involved in the research, development, and commercialization of acute migraine drugs.

The global acute migraine drugs market is driven by the factors such as the increasing prevalence of migraine, rising demand for innovative drugs, increasing awareness and diagnosis, and technological advancements in acute migraine drugs.

Market Dynamics

Rising Demand for Innovative Drugs Drives the Growth of the Acute Migraine Drugs Market

The demand for innovative drugs is also driven by the desire for more convenient and effective treatment modalities. The development of novel drug delivery systems, such as nasal sprays, injectable formulations, and transdermal patches, aims to enhance drug efficacy, improve patient compliance, and provide faster relief from migraine symptoms. These advancements contribute to market growth by meeting the evolving needs and preferences of patients.

Migraine is a complex neurological disorder, and there is a continuous need for more effective and targeted treatments to alleviate symptoms and improve patient outcomes. And the rising clinical trials leading to innovative drugs for the better treatment of acute migraine.

For instance, on June 13, 2023, Vistagen, a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders, announced that the European Patent Office (EPO) issued an intention to grant a patent for the treatment of migraine by nasal administration of PH80 nasal spray, one of the Company's five rapid-onset investigational neuroactive pherine therapeutics.

Increasing Awareness and Diagnosis Also Drive the Growth of the Acute Migraine Drugs Market

With increased awareness, individuals are more likely to seek medical help at the onset of migraine symptoms, leading to earlier intervention and treatment. Early treatment is associated with better outcomes, as it can help alleviate symptoms faster and potentially prevent the progression of migraines. The emphasis on early intervention fuels the demand for acute migraine drugs that provide rapid relief during migraine attacks.

As awareness of migraines grows, healthcare providers are increasingly educated about the diagnosis and management of the condition. Medical societies and organizations publish guidelines and recommendations for the treatment of migraines, emphasizing evidence-based approaches. These guidelines influence physicians' prescribing patterns, contributing to the increased utilization of acute migraine drugs.

High Cost of Drugs will Hamper the Growth of the Market

The high cost of drugs can make them inaccessible to a significant portion of the population, especially those without adequate health insurance coverage or limited financial resources. This can create barriers to access and prevent individuals from receiving appropriate treatment for their migraines. The affordability of drugs is a crucial factor in ensuring that patients can obtain the medications they need.

High drug costs can pose challenges in terms of reimbursement and insurance coverage. Insurance providers may have strict coverage policies or high co-payment requirements for expensive migraine drugs, limiting patient access. This can lead to delays in receiving treatment or even the use of less effective or more affordable alternatives, impacting patient outcomes.

COVID-19 Impact Analysis

The COVID-19 pandemic significantly impacted the global acute migraine drugs market. Clinical trials for new acute migraine drugs may have experienced delays or disruptions due to the pandemic. Restrictions on patient recruitment, limitations on on-site visits, and prioritization of COVID-19-related research affected the progression of clinical trials. These delays may have impacted the introduction of new treatments to the market.

Russia-Ukraine War Impact Analysis

The Russia-Ukraine conflict is estimated to have a moderate impact on the global acute migraine drugs market. The conflict can lead to disruptions in supply chains, including the transportation of pharmaceutical products and raw materials for acute migraine drugs. Border closures, trade restrictions, and increased security measures can impede the movement of goods, potentially causing delays or shortages in the availability of acute migraine drugs.

Segment Analysis

The global acute migraine drugs market is segmented based on drug type, route of administration, distribution channel, and region.

Triptans from the Drug Type Segment Accounts for 36.8% of the Acute Migraine Drugs Market Share

Triptans are available in various formulations and administration routes, allowing for flexibility and individualized treatment approaches. Oral tablets, nasal sprays, injectable formulations, and dissolving tablets offer different options for patients with acute migraine. The availability of different triptan options enhances patient convenience and increases the likelihood of finding a suitable treatment method, further enhancing market dominance.

Some triptan drugs have gained significant brand recognition and loyalty among healthcare providers and patients. Well-known brands have established themselves as trusted options, with physicians often prescribing them due to their familiarity and proven track record. This brand recognition and loyalty contribute to the continued dominance of triptans in the acute migraine drugs market.

Geographical Analysis

North America Accounted for Approximately 40.2% of the Market Share Owing to the Strong Research and Developments and Advanced Healthcare Infrastructure

North America boasts advanced healthcare infrastructure, including well-established healthcare systems, medical facilities, and research institutions. These resources support the development, approval, and distribution of acute migraine drugs. The region's robust healthcare infrastructure enables access to innovative treatments including drugs, and enhances clinical trials for innovative drugs.

North America has a strong focus on research and development activities in the pharmaceutical industry. The region is home to numerous pharmaceutical companies, academic institutions, and research organizations that actively contribute to the development of new acute migraine drugs. The presence of these entities and the availability of funding for research and development initiatives drive innovations further enhancing the market growth in the region.

For instance, on November 16, 2022, AbbVie announced that Health Canada has approved UBRELVY (ubrogepant tablet) for the acute treatment of migraine, with or without aura, in adults. UBRELVY is the first orally-administered calcitonin gene-related peptide (CGRP) receptor antagonist (gepant) for the treatment of migraine attacks once they start.

Competitive Landscape

The major global players in the acute migraine drugs market include: Teva Pharmaceuticals, F Hoffmann-la Roche Ltd, Johnson & Johnson, Pfizer Inc., AstraZeneca, Amgen Inc., Merck & Co., Novartis AG, Eli lilly and Company, and Sun Pharma.

Why Purchase the Report?

  • To visualize the global acute migraine drugs market segmentation based on drug type, route of administration, distribution channel, and region, as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of acute migraine drugs market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as excel consisting of key products of all the major players.

The global acute migraine drugs market report would provide approximately 53 tables, 54 figures, and 195 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Drug Type
  • 3.2. Snippet by Route of Administration
  • 3.3. Snippet by Distribution Channel
  • 3.4. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Rising Demand for Innovative Drugs
      • 4.1.1.2. Increasing Awareness and Diagnosis
    • 4.1.2. Restraints
      • 4.1.2.1. High Cost of the Drugs
    • 4.1.3. Opportunity
      • 4.1.3.1. Technological Advancements and Novel Drug Launches
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's 5 Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID-19
    • 6.1.2. Scenario During COVID-19
    • 6.1.3. Scenario Post COVID-19
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturer's Strategic Initiatives
  • 6.6. Conclusion

7. By Drug Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 7.1.2. Market Attractiveness Index, By Drug Type
  • 7.2. Triptans *
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. NSAIDs
  • 7.4. Ergot Alkaloids
  • 7.5. Others

8. By Route of Administration

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 8.1.2. Market Attractiveness Index, By Route of Administration
  • 8.2. Oral *
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Parenteral
  • 8.4. Nasal
  • 8.5. Others

9. By Distribution Channel

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 9.1.2. Market Attractiveness Index, By Distribution Channel
  • 9.2. Hospital Pharmacies *
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Retail Pharmacies
  • 9.4. Online Pharmacies

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. U.K.
      • 10.3.6.3. France
      • 10.3.6.4. Spain
      • 10.3.6.5. Italy
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia-Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia-Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

11. Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

  • 12.1. Teva Pharmaceuticals *
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Financial Overview
    • 12.1.4. Key Developments
  • 12.2. F Hoffmann-la Roche Ltd
  • 12.3. Johnson & Johnson
  • 12.4. Pfizer Inc.
  • 12.5. AstraZeneca
  • 12.6. Amgen Inc.
  • 12.7. Merck & Co.
  • 12.8. Novartis AG
  • 12.9. Eli Lilly and Company
  • 12.10. Sun Pharma

LIST NOT EXHAUSTIVE

13. Appendix

  • 13.1. About Us and Services
  • 13.2. Contact Us